Review the Research<\/p>\n
Get summaries of key research on vitamin D and COVID-19<\/h5><\/div><\/div><\/div><\/div><\/div>\nHospital and Laboratory Outcomes of Patients with COVID-19 who Received Vitamin D Supplementation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials<\/span><\/h1><\/div>Take Home Message<\/span><\/h2><\/div>This meta-analysis found that vitamin D supplementation reduced the risk of ICU admission<\/span> in patients with COVID-19<\/span> but not for other COVID-19 outcomes.<\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div>Results<\/span><\/h2><\/div><\/div><\/div>\n- 9 RCTs including 1586 confirmed COVID-19 patients with a mean age of 56.41\u00b111.69 were included in the analysis.\u00a0\u00a0<\/span>\u00a0<\/span><\/li>\n
- The intervention and control groups ranged from 16 to 274 participants. Most patients received oral vitamin D administration, but in one study patients received vitamin D via intramuscular injection.<\/span>\u00a0<\/span><\/li>\n
- Patients receiving vitamin D <\/span>showed a significant reduction in ICU admission, as well as a greater change in vitamin D levels when compared to control groups.\u00a0<\/span>\u00a0<\/span><\/li>\n
- There was no significant difference between vitamin D and control groups for all other hospital and laboratory outcomes studied.\u00a0<\/span>\u00a0<\/span><\/li>\n<\/ul>\n
\u00a0<\/span><\/p>\n<\/div><\/div><\/div>![](\"https:\/\/www.vitamindandme.org\/wp-content\/uploads\/2023\/05\/23-5-Zaazouee-300x193.jpg\" "\\"Senior")
<\/span><\/div><\/div><\/div><\/div><\/div>Who<\/span><\/h2><\/div>Nine<\/span> clinical <\/span>studie<\/span>s including 1596 <\/span>adult <\/span>patients with confirmed COVID-19 infection<\/span> were included in the analys<\/span>e<\/span>s.<\/span><\/span>\u00a0<\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div>Things to Keep in Mind<\/span><\/h2><\/div>\n- High heterogeneity was observed between studies, such as different populations\u2019 characteristics including age, sex, race, the severity of COVID-19 symptoms, treatment protocol, and associated comorbidities.<\/span>\u00a0<\/span><\/li>\n
- Vitamin D treatment varied in dose, form, timing of administration, and patient\u2019s baseline levels of vitamin D. Patients received variable amounts of vitamin D, ranging from low to high doses (up to 500,000 IU), and from single dose to daily doses administered for up to 2 months.\u00a0<\/span>\u00a0<\/span><\/li>\n
- Not all studies included each of the outcomes evaluated.<\/span>\u00a0<\/span><\/li>\n<\/ul>\n<\/div><\/div><\/div><\/div><\/div>
Author\u2019s Conclusions<\/span><\/h2><\/div><\/div><\/div>“<\/span><\/h2><\/div><\/div><\/div>O<\/span>ur study suggested that vitamin D supplementation benefits COVID\u201019 patients by reducing ICU admission and increasing changes in vitamin D levels. However, it produces no difference in other outcomes compared to no vitamin D intake. The definite role of vitamin D on COVID\u201019 outcomes strongly needs further well-conducted and high-quality research, especially after its known effect on the body\u2019s immune system and defense mechanisms and the previously collected data on its benefits on certain respiratory diseases, including COVID-19.<\/span><\/p>\n<\/div><\/div><\/div>“<\/span><\/h2><\/div><\/div><\/div><\/div><\/div>Study Design<\/span><\/h2><\/div>\n- This systematic review and meta-analysis evaluated the effect of vitamin D supplementation on hospital and laboratory outcomes in patients with COVID-19.\u00a0<\/span>\u00a0<\/span><\/li>\n
- Five databases (PubMed, Embase, Scopus, Web of Science, and Cochrane Library) and clinicaltrials.gov were searched until July 2022.\u00a0<\/span>\u00a0<\/span><\/li>\n
- Eligible randomized clinical trials (RCTs) <\/span>included COVID-19 patients who received vitamin D supplementation (any type) and compared hospital and laboratory outcomes with similar patients who received no intervention or placebo.\u00a0<\/span>\u00a0<\/span><\/li>\n
- Hospital outcomes included the need for intensive care unit (ICU) admission, ventilation and oxygen therapy, risk of death, and length of hospital stay. Laboratory outcomes included levels of vitamin D, C-reactive protein, interleukin-6, lactate dehydrogenase, calcium concentration, creatinine, d-dimer, neutrophil count, lymphocyte count, platelet count, and leucocytes.<\/span><\/li>\n<\/ul>\n
\u00a0<\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div>Reference<\/span><\/h2><\/div>Zaazouee<\/span> MS, <\/span>Eleisawy<\/span> M, <\/span>Abdalalaziz<\/span> AM, <\/span>Elhady<\/span> MM, Ali OA, <\/span>Abdelbari<\/span> TM, Hasan SM, <\/span>Almadhoon<\/span> HW, Ahmed AY, <\/span>Fassad<\/span> AS, <\/span>Elgendy<\/span> R, Abdel-Baset EA, <\/span>Elsayed<\/span> HA, <\/span>Elsnhory<\/span> AB, <\/span>Abdraboh<\/span> AB, <\/span>Faragalla<\/span> HM, <\/span>Elshanbary<\/span> AA, <\/span>Kensara<\/span> OA, Abdel-<\/span>Daim<\/span> MM. Hospital and laboratory outcomes of patients with COVID-19 who received vitamin D supplementation: a systematic review and meta-analysis of randomized controlled trials. <\/span>Naunyn<\/span> Schmiedebergs<\/span> Arch <\/span>Pharmacol<\/span>. 2023 Apr;396(4):607-620. <\/span>doi<\/span>: 10.1007\/s00210-022-02360-x. <\/span>Epub<\/span> 2022 Dec 12.<\/span><\/p>\n<\/div><\/div><\/div>
Hospital and Laboratory Outcomes of Patients with COVID-19 who Received Vitamin D Supplementation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials<\/span><\/h1><\/div>Take Home Message<\/span><\/h2><\/div>This meta-analysis found that vitamin D supplementation reduced the risk of ICU admission<\/span> in patients with COVID-19<\/span> but not for other COVID-19 outcomes.<\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div>Results<\/span><\/h2><\/div><\/div><\/div>\n- 9 RCTs including 1586 confirmed COVID-19 patients with a mean age of 56.41\u00b111.69 were included in the analysis.\u00a0\u00a0<\/span>\u00a0<\/span><\/li>\n
- The intervention and control groups ranged from 16 to 274 participants. Most patients received oral vitamin D administration, but in one study patients received vitamin D via intramuscular injection.<\/span>\u00a0<\/span><\/li>\n
- Patients receiving vitamin D <\/span>showed a significant reduction in ICU admission, as well as a greater change in vitamin D levels when compared to control groups.\u00a0<\/span>\u00a0<\/span><\/li>\n
- There was no significant difference between vitamin D and control groups for all other hospital and laboratory outcomes studied.\u00a0<\/span>\u00a0<\/span><\/li>\n<\/ul>\n
\u00a0<\/span><\/p>\n<\/div><\/div><\/div><\/span><\/div><\/div><\/div><\/div><\/div>Who<\/span><\/h2><\/div>Nine<\/span> clinical <\/span>studie<\/span>s including 1596 <\/span>adult <\/span>patients with confirmed COVID-19 infection<\/span> were included in the analys<\/span>e<\/span>s.<\/span><\/span>\u00a0<\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div>Things to Keep in Mind<\/span><\/h2><\/div>\n- High heterogeneity was observed between studies, such as different populations\u2019 characteristics including age, sex, race, the severity of COVID-19 symptoms, treatment protocol, and associated comorbidities.<\/span>\u00a0<\/span><\/li>\n
- Vitamin D treatment varied in dose, form, timing of administration, and patient\u2019s baseline levels of vitamin D. Patients received variable amounts of vitamin D, ranging from low to high doses (up to 500,000 IU), and from single dose to daily doses administered for up to 2 months.\u00a0<\/span>\u00a0<\/span><\/li>\n
- Not all studies included each of the outcomes evaluated.<\/span>\u00a0<\/span><\/li>\n<\/ul>\n<\/div><\/div><\/div><\/div><\/div>
Author\u2019s Conclusions<\/span><\/h2><\/div><\/div><\/div>“<\/span><\/h2><\/div><\/div><\/div>O<\/span>ur study suggested that vitamin D supplementation benefits COVID\u201019 patients by reducing ICU admission and increasing changes in vitamin D levels. However, it produces no difference in other outcomes compared to no vitamin D intake. The definite role of vitamin D on COVID\u201019 outcomes strongly needs further well-conducted and high-quality research, especially after its known effect on the body\u2019s immune system and defense mechanisms and the previously collected data on its benefits on certain respiratory diseases, including COVID-19.<\/span><\/p>\n<\/div><\/div><\/div>“<\/span><\/h2><\/div><\/div><\/div><\/div><\/div>Study Design<\/span><\/h2><\/div>\n- This systematic review and meta-analysis evaluated the effect of vitamin D supplementation on hospital and laboratory outcomes in patients with COVID-19.\u00a0<\/span>\u00a0<\/span><\/li>\n
- Five databases (PubMed, Embase, Scopus, Web of Science, and Cochrane Library) and clinicaltrials.gov were searched until July 2022.\u00a0<\/span>\u00a0<\/span><\/li>\n
- Eligible randomized clinical trials (RCTs) <\/span>included COVID-19 patients who received vitamin D supplementation (any type) and compared hospital and laboratory outcomes with similar patients who received no intervention or placebo.\u00a0<\/span>\u00a0<\/span><\/li>\n
- Hospital outcomes included the need for intensive care unit (ICU) admission, ventilation and oxygen therapy, risk of death, and length of hospital stay. Laboratory outcomes included levels of vitamin D, C-reactive protein, interleukin-6, lactate dehydrogenase, calcium concentration, creatinine, d-dimer, neutrophil count, lymphocyte count, platelet count, and leucocytes.<\/span><\/li>\n<\/ul>\n
\u00a0<\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div>Reference<\/span><\/h2><\/div>Zaazouee<\/span> MS, <\/span>Eleisawy<\/span> M, <\/span>Abdalalaziz<\/span> AM, <\/span>Elhady<\/span> MM, Ali OA, <\/span>Abdelbari<\/span> TM, Hasan SM, <\/span>Almadhoon<\/span> HW, Ahmed AY, <\/span>Fassad<\/span> AS, <\/span>Elgendy<\/span> R, Abdel-Baset EA, <\/span>Elsayed<\/span> HA, <\/span>Elsnhory<\/span> AB, <\/span>Abdraboh<\/span> AB, <\/span>Faragalla<\/span> HM, <\/span>Elshanbary<\/span> AA, <\/span>Kensara<\/span> OA, Abdel-<\/span>Daim<\/span> MM. Hospital and laboratory outcomes of patients with COVID-19 who received vitamin D supplementation: a systematic review and meta-analysis of randomized controlled trials. <\/span>Naunyn<\/span> Schmiedebergs<\/span> Arch <\/span>Pharmacol<\/span>. 2023 Apr;396(4):607-620. <\/span>doi<\/span>: 10.1007\/s00210-022-02360-x. <\/span>Epub<\/span> 2022 Dec 12.<\/span><\/p>\n<\/div><\/div><\/div>
Take Home Message<\/span><\/h2><\/div>This meta-analysis found that vitamin D supplementation reduced the risk of ICU admission<\/span> in patients with COVID-19<\/span> but not for other COVID-19 outcomes.<\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div>Results<\/span><\/h2><\/div><\/div><\/div>\n- 9 RCTs including 1586 confirmed COVID-19 patients with a mean age of 56.41\u00b111.69 were included in the analysis.\u00a0\u00a0<\/span>\u00a0<\/span><\/li>\n
- The intervention and control groups ranged from 16 to 274 participants. Most patients received oral vitamin D administration, but in one study patients received vitamin D via intramuscular injection.<\/span>\u00a0<\/span><\/li>\n
- Patients receiving vitamin D <\/span>showed a significant reduction in ICU admission, as well as a greater change in vitamin D levels when compared to control groups.\u00a0<\/span>\u00a0<\/span><\/li>\n
- There was no significant difference between vitamin D and control groups for all other hospital and laboratory outcomes studied.\u00a0<\/span>\u00a0<\/span><\/li>\n<\/ul>\n
\u00a0<\/span><\/p>\n<\/div><\/div><\/div><\/span><\/div><\/div><\/div><\/div><\/div>Who<\/span><\/h2><\/div>Nine<\/span> clinical <\/span>studie<\/span>s including 1596 <\/span>adult <\/span>patients with confirmed COVID-19 infection<\/span> were included in the analys<\/span>e<\/span>s.<\/span><\/span>\u00a0<\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div>Things to Keep in Mind<\/span><\/h2><\/div>\n- High heterogeneity was observed between studies, such as different populations\u2019 characteristics including age, sex, race, the severity of COVID-19 symptoms, treatment protocol, and associated comorbidities.<\/span>\u00a0<\/span><\/li>\n
- Vitamin D treatment varied in dose, form, timing of administration, and patient\u2019s baseline levels of vitamin D. Patients received variable amounts of vitamin D, ranging from low to high doses (up to 500,000 IU), and from single dose to daily doses administered for up to 2 months.\u00a0<\/span>\u00a0<\/span><\/li>\n
- Not all studies included each of the outcomes evaluated.<\/span>\u00a0<\/span><\/li>\n<\/ul>\n<\/div><\/div><\/div><\/div><\/div>
Author\u2019s Conclusions<\/span><\/h2><\/div><\/div><\/div>“<\/span><\/h2><\/div><\/div><\/div>O<\/span>ur study suggested that vitamin D supplementation benefits COVID\u201019 patients by reducing ICU admission and increasing changes in vitamin D levels. However, it produces no difference in other outcomes compared to no vitamin D intake. The definite role of vitamin D on COVID\u201019 outcomes strongly needs further well-conducted and high-quality research, especially after its known effect on the body\u2019s immune system and defense mechanisms and the previously collected data on its benefits on certain respiratory diseases, including COVID-19.<\/span><\/p>\n<\/div><\/div><\/div>“<\/span><\/h2><\/div><\/div><\/div><\/div><\/div>Study Design<\/span><\/h2><\/div>\n- This systematic review and meta-analysis evaluated the effect of vitamin D supplementation on hospital and laboratory outcomes in patients with COVID-19.\u00a0<\/span>\u00a0<\/span><\/li>\n
- Five databases (PubMed, Embase, Scopus, Web of Science, and Cochrane Library) and clinicaltrials.gov were searched until July 2022.\u00a0<\/span>\u00a0<\/span><\/li>\n
- Eligible randomized clinical trials (RCTs) <\/span>included COVID-19 patients who received vitamin D supplementation (any type) and compared hospital and laboratory outcomes with similar patients who received no intervention or placebo.\u00a0<\/span>\u00a0<\/span><\/li>\n
- Hospital outcomes included the need for intensive care unit (ICU) admission, ventilation and oxygen therapy, risk of death, and length of hospital stay. Laboratory outcomes included levels of vitamin D, C-reactive protein, interleukin-6, lactate dehydrogenase, calcium concentration, creatinine, d-dimer, neutrophil count, lymphocyte count, platelet count, and leucocytes.<\/span><\/li>\n<\/ul>\n
\u00a0<\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div>Reference<\/span><\/h2><\/div>Zaazouee<\/span> MS, <\/span>Eleisawy<\/span> M, <\/span>Abdalalaziz<\/span> AM, <\/span>Elhady<\/span> MM, Ali OA, <\/span>Abdelbari<\/span> TM, Hasan SM, <\/span>Almadhoon<\/span> HW, Ahmed AY, <\/span>Fassad<\/span> AS, <\/span>Elgendy<\/span> R, Abdel-Baset EA, <\/span>Elsayed<\/span> HA, <\/span>Elsnhory<\/span> AB, <\/span>Abdraboh<\/span> AB, <\/span>Faragalla<\/span> HM, <\/span>Elshanbary<\/span> AA, <\/span>Kensara<\/span> OA, Abdel-<\/span>Daim<\/span> MM. Hospital and laboratory outcomes of patients with COVID-19 who received vitamin D supplementation: a systematic review and meta-analysis of randomized controlled trials. <\/span>Naunyn<\/span> Schmiedebergs<\/span> Arch <\/span>Pharmacol<\/span>. 2023 Apr;396(4):607-620. <\/span>doi<\/span>: 10.1007\/s00210-022-02360-x. <\/span>Epub<\/span> 2022 Dec 12.<\/span><\/p>\n<\/div><\/div><\/div>
This meta-analysis found that vitamin D supplementation reduced the risk of ICU admission<\/span> in patients with COVID-19<\/span> but not for other COVID-19 outcomes.<\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div> \u00a0<\/span><\/p>\n<\/div><\/div><\/div> Nine<\/span> clinical <\/span>studie<\/span>s including 1596 <\/span>adult <\/span>patients with confirmed COVID-19 infection<\/span> were included in the analys<\/span>e<\/span>s.<\/span><\/span>\u00a0<\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div> O<\/span>ur study suggested that vitamin D supplementation benefits COVID\u201019 patients by reducing ICU admission and increasing changes in vitamin D levels. However, it produces no difference in other outcomes compared to no vitamin D intake. The definite role of vitamin D on COVID\u201019 outcomes strongly needs further well-conducted and high-quality research, especially after its known effect on the body\u2019s immune system and defense mechanisms and the previously collected data on its benefits on certain respiratory diseases, including COVID-19.<\/span><\/p>\n<\/div><\/div><\/div> \u00a0<\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div> Zaazouee<\/span> MS, <\/span>Eleisawy<\/span> M, <\/span>Abdalalaziz<\/span> AM, <\/span>Elhady<\/span> MM, Ali OA, <\/span>Abdelbari<\/span> TM, Hasan SM, <\/span>Almadhoon<\/span> HW, Ahmed AY, <\/span>Fassad<\/span> AS, <\/span>Elgendy<\/span> R, Abdel-Baset EA, <\/span>Elsayed<\/span> HA, <\/span>Elsnhory<\/span> AB, <\/span>Abdraboh<\/span> AB, <\/span>Faragalla<\/span> HM, <\/span>Elshanbary<\/span> AA, <\/span>Kensara<\/span> OA, Abdel-<\/span>Daim<\/span> MM. Hospital and laboratory outcomes of patients with COVID-19 who received vitamin D supplementation: a systematic review and meta-analysis of randomized controlled trials. <\/span>Naunyn<\/span> Schmiedebergs<\/span> Arch <\/span>Pharmacol<\/span>. 2023 Apr;396(4):607-620. <\/span>doi<\/span>: 10.1007\/s00210-022-02360-x. <\/span>Epub<\/span> 2022 Dec 12.<\/span><\/p>\n<\/div><\/div><\/div>Results<\/span><\/h2><\/div><\/div><\/div>
\n
<\/span><\/div><\/div><\/div><\/div><\/div>Who<\/span><\/h2><\/div>
Things to Keep in Mind<\/span><\/h2><\/div>
\n
Author\u2019s Conclusions<\/span><\/h2><\/div><\/div><\/div>
“<\/span><\/h2><\/div><\/div><\/div>
“<\/span><\/h2><\/div><\/div><\/div><\/div><\/div>
Study Design<\/span><\/h2><\/div>
\n
Reference<\/span><\/h2><\/div>